Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Moleculin Biotech ( (MBRX) ) has issued an update.
At the Annual Meeting, held on October 24, 2024, Moleculin Biotech, Inc. stockholders voted on multiple proposals, including the election of directors and the ratification of Grant Thornton LLP as independent auditors. Significant outcomes included the approval of the 2024 Stock Plan and a non-binding resolution on executive compensation. Stockholders also approved changes related to stock issuance and warrant repricing to comply with Nasdaq rules, although a proposal to eliminate supermajority voting requirements did not pass.
See more insights into MBRX stock on TipRanks’ Stock Analysis page.

